
GERD, Barrett’s Esophagus and GI Screenings
The landscape of gastrointestinal care is shifting fundamentally, driven by newly released consensus criteria, next-generation acid-suppressive therapies, and evolving screening strategies.
Dr. Jason Farrell will break down the essential updates from the 2024 Lyon 2.0 Consensus, which establishes new, objective standard parameters for diagnosing GERD based on physiology and advanced monitoring metrics rather than symptom response alone. The presentation will critically evaluate the comparative pharmacology of traditional PPIs against Vonoprazan (PCAB) - the first novel acid-suppressive mechanism introduced in decades - and outline precise clinical criteria for matching refractory patients to endoscopic or surgical anti-reflux interventions. Finally, the session will review the latest risk-stratified AGA 2025 surveillance intervals for Barrett’s Esophagus and dissect the clinical realities of emerging blood-based colorectal cancer screening tests. Attendees will leave equipped with evidence-based principles ready for immediate clinical execution.
Key Learning Objectives:
REGISTER HERE!
If your insurance requires a referral or prior authorization, our billing office will make every effort to obtain it before services are rendered. If you choose to proceed without required authorization, insurance may deny coverage. If you are a Medicare patient, you may be asked to sign an Advanced Beneficiary Notice (ABN) acknowledging financial responsibility if insurance does not pay. If you are enrolled in a commercial insurance plan you will be asked to sign a non-covered services form.